RNA-seq of human NSCLC cell line treated with Tramatinib or Lorlatinib, at different time points
To better understand the differences between different ALK inhibitors on ALK positive NSCLC cell lines, we performed RNA-seq analysis on samples treated with 2 types of ALK inhibitors: Tramatinib and Lorlatinib. Samples taken 6h and 24h after treatment